Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal
Publication
, Conference
Ritchie, EK; Catchatourian, R; Klisovic, RB; Deininger, MW; Erba, HP; Radich, JP; Savona, MR; Warsi, G; Paley, CS; Dautaj, I; Lin, FP; Mauro, MJ
Published in: BLOOD
December 3, 2015
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Ritchie, E. K., Catchatourian, R., Klisovic, R. B., Deininger, M. W., Erba, H. P., Radich, J. P., … Mauro, M. J. (2015). Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal. In BLOOD (Vol. 126). Orlando, FL: AMER SOC HEMATOLOGY.
Ritchie, Ellen K., Rosalind Catchatourian, Rebecca B. Klisovic, Michael W. Deininger, Harry P. Erba, Jerald P. Radich, Michael R. Savona, et al. “Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal.” In BLOOD, Vol. 126. AMER SOC HEMATOLOGY, 2015.
Ritchie EK, Catchatourian R, Klisovic RB, Deininger MW, Erba HP, Radich JP, et al. Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal. In: BLOOD. AMER SOC HEMATOLOGY; 2015.
Ritchie, Ellen K., et al. “Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal.” BLOOD, vol. 126, no. 23, AMER SOC HEMATOLOGY, 2015.
Ritchie EK, Catchatourian R, Klisovic RB, Deininger MW, Erba HP, Radich JP, Savona MR, Warsi G, Paley CS, Dautaj I, Lin FP, Mauro MJ. Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal. BLOOD. AMER SOC HEMATOLOGY; 2015.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 3, 2015
Volume
126
Issue
23
Location
Orlando, FL
Publisher
AMER SOC HEMATOLOGY
Conference Name
57th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology